Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Inhibitors of Kelch-like ECH-associated protein 1 (Keap1) increase the activity of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) by stalling its ubiquitination and degradation. This enhances the expression of genes encoding proteins involved in drug detoxification, redox homeostasis, and mitochondrial function. Nrf2 activation offers a potential therapeutic approach for conditions including Alzheimer's and Parkinson's diseases, vascular inflammation, and chronic obstructive airway disease. Non-electrophilic Keap1-Nrf2 protein-protein interaction (PPI) inhibitors may have improved toxicity profiles and different pharmacological properties to cysteine-reactive electrophilic inhibitors. Here, we describe and characterize a series of phenyl bis-sulfonamide PPI inhibitors that bind to Keap1 at submicromolar concentrations. Structural studies reveal that the compounds bind to Keap1 in a distinct "peptidomimetic" conformation that resembles the Keap1-Nrf2 ETGE peptide complex. This is different to other small molecule Keap1-Nrf2 PPI inhibitors, including bicyclic aryl bis-sulfonamides, offering a starting point for new design approaches to Keap1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Figure 4 Dose-dependent induction of NQO1 [NAD(P)H-dependent quinone oxidoreductase-1] by selected (A) Keap1-Nrf2 PPI inhibitors: 10 (◀), 11 (▼), 31 (▲), 32 (●), 36 (⧫), and 38 (■) and (B) electrophilic Nrf2 activators: DMF (★) and CDDO-Me (▶).](https://figures.cochat.ai/paper-figures/270851c67c154edc99d52e5367aa1f66/phenyl-bis-sulfonamide-keap1-nrf2-proteinprotein-interaction-inhibitors-with-an-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, another Keap1-Nrf2 PPI inhibitor 74, which combined conformational features significantly similar to the Keap1-Nrf2 ETGE complex, revealed the unique inhibition mechanism and provided an innovative strategy for the development of new Keap1-Nrf2 PPI inhibitors.592”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [592]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939 · cited 2×
“Analogues having both carboxylates substituted for carboxamides (compound 60 ) or nitriles (compound 61 ) did not show activity at 10 μ M, results that are consistent with the SAR obtained from the 2-benzyloxy derivatives 40 and 41 .”
InfluentialLigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
Laskowski, R. A., & Swindells, M. B. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200227u · Cited by 6,471
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties
DUNN, K. C., AOTAKI-KEEN, A. E., PUTKEY, F. R., & HJELMELAND, L. M. (1996) · Experimental Eye Research · doi:10.1006/exer.1996.0020 · Cited by 1,330
Research works printed but not linked: 1
- Valko K. L. Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization; John Wiley & Sons, Inc.: New Jersey, USA, 2014; p 450.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“592 In summary, inhibition or activation of fundamental pathological interactions presents an alternative therapeutic avenue for AD.”
BackgroundAdvances and challenges in therapeutic targeting of NRF2
Dinkova-Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 266
Self-citationThe Role of Organosulfur Compounds as Nrf2 Activators and Their Antioxidant Effects
Egbujor, M. C., Petrosino, M., Zuhra, K., & Saso, L. (2022) · Antioxidants · doi:10.3390/antiox11071255 · Cited by 83
Advances in developing noncovalent small molecules targeting Keap1
Barreca, M., Qin, Y., Cadot, M. E. H., Barraja, P., & Bach, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103800 · Cited by 47
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1–Nrf2 PPI Inhibitor
Otake, K., Ubukata, M., Nagahashi, N., Ogawa, N., Hantani, Y., Hantani, R., Adachi, T., Nomura, A., Yamaguchi, K., Maekawa, M., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00067 · Cited by 30
An updated patent review of Nrf2 activators (2020-present)
Zhao, Z., Dong, R., Cui, K., You, Q., & Jiang, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2178299 · Cited by 28
Zhao, Z., Dong, R., You, Q., & Jiang, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00712 · Cited by 28
A cell-active cyclic peptide targeting the Nrf2/Keap1 protein–protein interaction
Iegre, J., Krajčovičová, S., Gunnarsson, A., Wissler, L., Käck, H., Łuchniak, A., Tångefjord, S., Narjes, F., & Spring, D. R. (2023) · Chemical Science · doi:10.1039/d3sc04083f · Cited by 26
Alcohol addiction and Alzheimer’s disease: a molecular collision course
Chang, J.-S., Huang, H., Yuan, M., Zhou, Y., Liu, D., Zhan, K., & Zhu, L. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03619-6 · Cited by 19
Wang, Z., Feng, W., Li, X., Yun, X., Wu, S., Du, L., & Wang, H. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103035 · Cited by 19
Chen, B., Liu, C., Cong, W., Gao, F., Zou, Y., Su, L., Liu, L., Hillisch, A., Lehmann, L. E., Bierer, D. E., et al. (2023) · Chemical Science · doi:10.1039/d3sc04279k · Cited by 16
Abed, D. A., Ali, A. R., Lee, S., Nguyen, M.-U., Verzi, M. P., & Hu, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115302 · Cited by 14
Otake, K., Hara, Y., Ubukata, M., Inoue, M., Nagahashi, N., Motoda, D., Ogawa, N., Hantani, Y., Hantani, R., Adachi, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02171 · Cited by 12
Dakhlaoui, I., Bernard, P. J., Pietrzak, D., Simakov, A., Maj, M., Refouvelet, B., Béduneau, A., Cornu, R., Jóźwiak, K., Chabchoub, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119742 · Cited by 13
Lee, S., Ali, A. R., Abed, D. A., Nguyen, M.-U., Verzi, M. P., & Hu, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116104 · Cited by 11
Sun, Y., Zheng, L., Yang, B., Ge, S., Li, Q., Zhang, M., Shen, S., & Yin, Y. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2124408 · Cited by 11
Cho, H., & Lee, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118485 · Cited by 10
Naidu, S. D., Dikovskaya, D., Walker, J. M., Yee, C. J. Y. L. J., Cafferkey, A. J., Tatsuno, M., Feng, J., Moore, T. W., Johnson, T., Honda, T., et al. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00045b · Cited by 6
Self-citationPatenting perspective on Keap1 inhibitors (2019–2024)
Luo, Y., Yang, W., Zhang, Y., Jiang, S., Zhu, J., Li, X., You, Q., & Lu, M. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2462844 · Cited by 6
“The cocrystal complex of Keap1 with 40 revealed that it binds to Keap1 in a unique ‘peptidomimetic’ conformation, resembling the Keap1-Nrf2 ETGE peptide complex (Figure 12(a)) [152].”
Sang, Y.-L., Huang, W., Lin, J., Liu, Y., Zhou, Y., Chang, Y., Sun, X., Yu, H., & Kong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117650 · Cited by 5
Electro-promoted radical-radical cross-coupling reaction to synthesize sulfonamides
Gong, H., Fu, H., Lu, C. T., & Cai, C. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.134315 · Cited by 4
Georgakopoulos, N., Talapatra, S. K., Naidu, S. D., Dikovskaya, D., Higgins, M., Gatliff, J., Nikoloudaki, R., Schaap, M., Walker, J. M., Wardby, C., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103924 · Cited by 4
“Kelch domain was performed as described previously [23,31,32].”
InfluentialSelf-citationKEAP1/NRF2 as a druggable target
Dinkova‐Kostova, A. T. (2023) · Arhiv za farmaciju · doi:10.5937/arhfarm73-43475 · Cited by 5
Self-citationGuo, Y., Wang, N., Tao, Z., Huang, X., Yu, W., Zeng, J., Liu, X., Chen, S., Hua, F., & Wang, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116599 · Cited by 3
Elsharkasi, M. M. O., Villani, B., Wells, G., & Kerr, F. (2025) · Brain and Neuroscience Advances · doi:10.1177/23982128251351360 · Cited by 4
“(c) End-point measurement of NQO1 activity in astrocytes following treatment with 40 µM DMF in either complete astrocyte or Neurobasal medias for 28 h. Data are presented as mean absorbance/ug total protein ± SEM (n = 5–9, three independent experiments).”
Self-citationMurwanti, R., Arifka, V. I., Anargya, R. D. P., Marbun, P., DAMAYANTI, A. N., SYAHPUTRA, A., Prinanda, H. H., & Ritmaleni, R. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02044-w
“Arg380-associated regions have been identified as part of the KEAP1 inhibitory pharmaco - phore in several natural compounds capable of modulating oxidative stress through NRF2 activation, including maslinic acid, 18-α-glycyrrhetinic acid, and resveratrol [73, 74].”
Park, H. R. (2026) · Nutrients · doi:10.3390/nu18071159
“Disruption of neurexin-1 β or its interaction with neuroligin-2 impairs GABAergic synaptic transmission and has been associated with increased seizure activity and epileptiform discharges [48].”
Li, S., Cai, W., Sang, Y., Wang, Y., Yong, Y., Kong, X., & Song, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110137
Wang, Q., Sopipong, W., Wells, G., & Kozielski, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.19.760127
Self-citationPoonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“This opens up exciting new possibilities for the creation of cutting-edge and successful PPI-based treatments (283, 284).”
BindingDB (2024) · UC San Diego · doi:10.7270/q2bk1hnp
A Molecular Docking Comparison Between Chalcones and Macromolecule Natural Products
Alheety, N. F., Ali, M. A., Alheety, M. A., Aldahham, B. J. M., En-Nakra, F., Abbas, J. A., & Jasem, M. J. (2026) · Macromolecular Symposia · doi:10.1002/masy.70517
Metadata
- Authors
- Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., Javid, F., Dinkova-Kostova, A. T., Kozielski, F., & Wells, G.
- Affiliations
- Stevenage Bioscience Catalyst (GB)
- UCL School of Pharmacy (GB)
- University of Dundee (GB)
- Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, U.K.
- University of Huddersfield (GB)
- Corresponding author
- Wells, Geoffrey
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-05-12
- Volume
- 65
- Issue
- 10
- Pages
- 7380-7398
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC9150106
- OpenAlex
- W4280585810
- Cited by
- 33
- References
- 48
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Huddersfield Research Portal (University of Huddersfield) (submittedVersion, cc-by)
- Funders
- School of Pharmacy, University College London
- Royal Society of Chemistry
- University College London
- Biotechnology and Biological Sciences Research Council (BB/L01923X/1)
- Cancer Research UK (C9344/A10268)
- Maplethorpe Trust
- Bloomsbury Consortium
- MRC Proximity to Discovery
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Keap1, Nrf2, protein-protein interaction inhibitors, ubiquitination, drug detoxification, redox homeostasis, Alzheimer's disease, Parkinson's disease, vascular inflammation, chronic obstructive pulmonary disease
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Protein Binding, Sulfonamides, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.